Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Payables (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Payables for 13 consecutive years, with $48.9 million as the latest value for Q4 2025.

  • Quarterly Payables rose 12.11% to $48.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.9 million through Dec 2025, up 12.11% year-over-year, with the annual reading at $48.9 million for FY2025, 12.11% up from the prior year.
  • Payables for Q4 2025 was $48.9 million at Madrigal Pharmaceuticals, up from $44.9 million in the prior quarter.
  • The five-year high for Payables was $48.9 million in Q4 2025, with the low at $1.1 million in Q2 2021.
  • Average Payables over 5 years is $24.1 million, with a median of $21.5 million recorded in 2021.
  • Peak annual rise in Payables hit 2002.26% in 2021, while the deepest fall reached 78.68% in 2021.
  • Over 5 years, Payables stood at $21.4 million in 2021, then grew by 11.46% to $23.8 million in 2022, then grew by 17.67% to $28.0 million in 2023, then soared by 55.48% to $43.6 million in 2024, then grew by 12.11% to $48.9 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $48.9 million, $44.9 million, and $38.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.